About: Ertumaxomab

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Ertumaxomab Goto Sponge NotDistinct Permalink

An Entity of Type : yago:WikicatMonoclonalAntibodiesForTumors, within Data Space : wasabi.inria.fr associated with source document(s)

Ertumaxomab (trade name Rexomun) is a rat-murine hybrid monoclonal antibody designed to treat some types of cancer. It is a trifunctional antibody which works by linking T-lymphocytes and macrophages to the cancer cells. Phase II clinical trial evaluating the treatment of breast cancer was terminated due to change in Fresenius' development plans. (So they could concentrate on their other product catumaxomab (trade name Removab).)

Attributes	Values
type	Thing yago:Abstraction100002137 yago:PhysicalEntity100001930 yago:Part113809207 yago:Relation100031921 drug yago:Antibody115027189 yago:WikicatMonoclonalAntibodies chemical substance drug Chemical object umbel-rc:DrugProduct dbo:MonoclonalAntibody yago:Chemical114806838 yago:Compound114818238 yago:Macromolecule114944888 yago:Material114580897 yago:Matter100020827 yago:Molecule114682133 yago:OrganicCompound114727670 yago:Protein114728724 yago:Substance100019613 yago:Thing100002452 yago:Unit109465459 yago:MonoclonalAntibody115029781 yago:WikicatMonoclonalAntibodiesForTumors
label	Ertumaxomab Ertumaxomab إرتوماكسوماب
comment	L'ertumaxomab nome commerciale Rexomun, è un anticorpo monoclonale ibrido Topo/ratto, valutato in studi di fase II per il trattamento del tumore della mammella.Viene anche chiamato anticorpo tri-funzionale perché agisce collegando le cellule T, i macrofagi e le cellule cancerose insieme. Il target molecolare del farmaco è l'antigene HER2/neu e CD3 Ertumaxomab (trade name Rexomun) is a rat-murine hybrid monoclonal antibody designed to treat some types of cancer. It is a trifunctional antibody which works by linking T-lymphocytes and macrophages to the cancer cells. Phase II clinical trial evaluating the treatment of breast cancer was terminated due to change in Fresenius' development plans. (So they could concentrate on their other product catumaxomab (trade name Removab).) إرتوماكسوماب هو جسم مضاد وحيد النسيلة مجانس (جرذي-فأري) طوّر لعلاج بعض أنواع الأورام. أوقفت التجارب السريرية عليه في مرحلتها الثانية لاستخدامه في علاج سرطان الثدي بعد النتائج التي تحققت في ترازتوزوماب.
sameAs	Ertumaxomab Ertumaxomab Ertumaxomab Ertumaxomab Ertumaxomab Ertumaxomab Ertumaxomab
topic	Trifunctional antibody dbr:Rexomun dbr:List_of_drugs:_Re dbr:List_of_therapeutic_monoclonal_antibodies wikipedia-en:Ertumaxomab dbr:Ertumaxomab#this dbr:List_of_drugs:_Eq–Es
described by	https://covidontheweb.inria.fr:4443/about/id/entity/http/dbpedia.org/class/yago/Compound114818238 https://covidontheweb.inria.fr:4443/about/id/entity/http/dbpedia.org/class/yago/Chemical114806838 https://covidontheweb.inria.fr:4443/about/id/entity/http/dbpedia.org/resource/Rat https://covidontheweb.inria.fr:4443/about/id/entity/http/dbpedia.org/resource/Cancer_cell https://covidontheweb.inria.fr:4443/about/id/entity/http/dbpedia.org/resource/Monoclonal_antibody proxy:entity/http/dbpedia.org/resource/Rat https://covidontheweb.inria.fr:4443/about/id/entity/http/dbpedia.org/class/yago/OrganicCompound114727670
dbp:tradename	Rexomun
Subject	Abandoned drugs Immunology Monoclonal antibodies for tumors
dbo:wikiPageID	9042799(xsd:integer)
dbo:wikiPageRevisionID	949616828(xsd:integer)
dbo:wikiPageWikiLink	dbr:CD3_receptor dbr:HER2/neu Cancer Cancer cell Macrophage monoclonal antibody Rat Breast cancer Mouse Trifunctional antibody Clinical trial Abandoned drugs dbr:Fresenius_(company) Immunology Monoclonal antibodies for tumors dbr:Catumaxomab dbr:T-lymphocyte
is primary topic of	wikipedia-en:Ertumaxomab
wasDerivedFrom	wikipedia-en:Ertumaxomab?oldid=949616828&ns=0
http://purl.org/li...ics/gold/hypernym	Antibody
dbo:abstract	L'ertumaxomab nome commerciale Rexomun, è un anticorpo monoclonale ibrido Topo/ratto, valutato in studi di fase II per il trattamento del tumore della mammella.Viene anche chiamato anticorpo tri-funzionale perché agisce collegando le cellule T, i macrofagi e le cellule cancerose insieme. Il target molecolare del farmaco è l'antigene HER2/neu e CD3 Ertumaxomab (trade name Rexomun) is a rat-murine hybrid monoclonal antibody designed to treat some types of cancer. It is a trifunctional antibody which works by linking T-lymphocytes and macrophages to the cancer cells. Phase II clinical trial evaluating the treatment of breast cancer was terminated due to change in Fresenius' development plans. (So they could concentrate on their other product catumaxomab (trade name Removab).) إرتوماكسوماب هو جسم مضاد وحيد النسيلة مجانس (جرذي-فأري) طوّر لعلاج بعض أنواع الأورام. أوقفت التجارب السريرية عليه في مرحلتها الثانية لاستخدامه في علاج سرطان الثدي بعد النتائج التي تحققت في ترازتوزوماب.
dbp:source	axo
dbp:type	mab
dbp:atcPrefix	none
dbp:mabType	3(xsd:integer)
dbp:casNumber	509077(xsd:integer)
dbp:chemspiderid	none
dbp:target	dbr:CD3_receptor dbr:HER2/neu
dbp:unii	L5L45YGP1O
dbp:verifiedfields	changed
dbp:verifiedrevid	457120720(xsd:integer)
dbo:alternativeName	Rexomun
dbo:casNumber	509077-99-0
dbo:fdaUniiCode	L5L45YGP1O
dbo:wikiPageLength	2239(xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Drugbankcite dbt:Drugbox dbt:Chemspidercite

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software